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your cohort reached a target low-density lipoprotein (LDL) level.
Many proponents of medical management would comment that
perhaps these patients were not therefore optimally medically
managed. Do you think that the lack of statin effect is because the
LDL targets were not reached?Do you think achieving these targets
is a realistic goal in clinical studies and in real world experience?
Dr Mark F. Conrad. I think the LDL target is a very impor-
tant part of medical management, but I also think that the concept
of optimal medical management has become the Holy Grail of ca-
rotid disease. It seems like it can never be adequately accomplished
in normal practice. I think as we move forward with asymptomatic
carotid studies, we are going to see that patients in the medical
arms, with close patient monitoring and frequent medication and
laboratory checks, are going to do well. But in a real world expe-
rience, I think it is very difﬁcult to make sure that they are taking
their statin every day and that their LDL levels are where they need
to be.You have to also remember this cohort is from 2005 and
2006, so we focused more on LDL levels later in the study and
that could explain the low number of patients with adequate levels.
But, yes, if everybody had taken their statin every day and their
LDL levels were <100 mg/dL, the results might have been
different.
Dr Ali AbuRahma (Charleston, WVa). I have a few questions
for Dr Conrad:
(1) How many of your patients progressed to total carotid
occlusion and how many of these were symptomatic at
the time of occlusion?
(2) How could you distinguish between 70% to 90% steno-
sis vs 90% to 99% stenosis? In our laboratory, we have
difﬁculty distinguishing between these two categories
of stenoses using duplex ultrasound.
(3) Your conclusion differs somewhat from the North
American Symptomatic Carotid Endarterectomy Trial
(NASCET) conclusion in that the NASCET patients
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with 70% to 90% stenosis. I would appreciate your
response to these questions. Thank you.
Dr Conrad. Actually, very few went on to develop occlusions.
We only had 3 occlusions and they were all symptomatic at the
time.
With regard to our division between severe and very severe, it
has changed over time, but we currently use a peak systolic velocity
of 250 as the threshold for severe category. And a diastolic velocity of
125or a ratio of>4would put the patient into the 90% to 99% range.
With regard to the asymptomatic patients from NASCET, the
event rate for patients with 75% to 99% stenosis was 18.5% at
5 years.
Dr Bruce Perler (Baltimore, Md). I just have a question to
allow you to speculate a bit. Based on your data, how comfortable
would you be randomizing an asymptomatic patient with a >90%
stenosis, for example, in the Carotid Revascularization Endarterec-
tomy vs Stenting Trial (CREST) II? Could you comment on any
ethical concerns of randomizing such a patient based on what
you have just presented.
Dr Conrad. I think that is a great philosophical question. I
think that everybody has to decide for themselves if they think
that this is a surgery that helps asymptomatic people. I think it
does and we are a very aggressive group when it comes to treating
asymptomatic carotid disease. I have to say that I am not a fan of
randomizing anybody to medical therapy when it comes to severe
stenosis but would do so for a trial.
Dr Wesley Moore (Los Angeles, Calif). I really enjoyed your
presentation and I was struck by the high event rate that you re-
ported in your asymptomatic patient population. As I recall, it was
29% in 5 years. In the data from the Asymptomatic Carotid Artery
Stenosis (ACAS) trial, whichwas controlled by contrast angiography
and duplex ultrasound, the event rate at the end of 5 years for the
medically treated group was 11%, or approximately 2.2% per year.
Now, the argument that Anne Abbott and others have put
forth is that their observation suggests that the annual event rate
for patients with asymptomatic, hemodynamically signiﬁcant carotid
stenosis might now be down to approximately 1% per year. If that is
the case, then we would have a very difﬁcult time showing a beneﬁt
of intervention over best medical management. I think your obser-
vation that Dr Abbott and others might be looking at in patients
with lesser stenosis than we would consider for intervention is fair.
I do want to put in a pitch for participation in CREST II. We are
under the gun right now from a lot of sources reporting we are per-
forming needless surgeries based on reports by Abbott and others.
We need to prove the efﬁcacy of intervention plus contemporary
best medical management vs best medical management alone.
CREST II is our last best chance to accomplish this objective.
As far as making sure that we have high-grade stenosis patients
in CREST II, the threshold for stenosis entry will be a peak systolicvelocity of 300. I think that will probably answer the question as to
whether we are including the high-grade stenosis group.
But getting back to your event rate of 29% in 5 years, which is
much greater than anyone has reported to date, I am wondering if
there is something different about the selection of your patient
cohort vs that which was seen in ACAS? You might have identiﬁed
the Holy Grail in identifying the high-risk group. Please share that
information with us.
Dr Conrad. I appreciate your comments regarding CREST
II. It’s funny, when you present low stroke rates after carotid end-
arterectomy (CEA), the cardiologists say you are underreporting
them. Now, we are presenting higher stroke rates with medical
management and the concern is that we are overreporting them.
I think this is a sicker group of patients than in ACAS because
many were not considered candidates for endarterectomy. We did
not go back and examine plaque morphology to predict symptom
development. We relied on the degree of stenosis for that.
Dr A. Ross Naylor (Bushby, United Kingdom). As Wes
Moore has just said, the key issue here is that you seem to have
identiﬁed a cohort who are behaving like symptomatic patients.
To my knowledge, no natural history or randomized study has
ever shown symptoms at such a high rate at 12 months, as you
are currently reporting. Accordingly, I think it would be wrong
to use this study to conclude that there is no need for reviewing
practice in asymptomatic patients.
I would also point out that there is a lot of guff being promul-
gated on the inclusion of moderate stenoses in the debate on
contemporary natural history studies. For example, if you compare
the ﬁrst 5 years of ACAS (1995), and the ﬁrst 5 years of Asymp-
tomatic Carotid Surgery Trial (ACST; 2004), and the second
5 years of ACST (2010), there have been sustained reductions in
the 5-year risk of any stroke and ipsilateral stroke across all three
time periods. So there is something out of kilter with your study
results compared with everything else that is going on.
Dr Patrick Geraghty (St. Louis, Mo). The 10-year follow-up
data from the ACST trial actually supported an aggressive
approach to CEA, in my opinion, because they analyzed patients
who were taking lipid-lowering therapy as a separate subset.
Lipid-lowering therapy lowered event rates in the immediate and
deferred arms, but patients still received more beneﬁt from the im-
mediate CEA. So I congratulate you for investigating this. I’ll let
Dr Cambria address your event rates; my point is that I do not
believe we should abandon CEA for asymptomatic disease quite
yet.
Dr Richard Cambria (Boston, Mass). I just wanted to correct
Dr Naylor. In the NASCET natural history study of asymptomatic
carotid lesions, for those with a surgically signiﬁcant lesion of
$60% according to the NASCET criteria, the overall annualized
risk was 2% per year. In those with 75% to 99% stenosis it was
4% per year, which approximates the data shown here.
